Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Liabilities and Shareholders Equity (2016 - 2025)

UroGen Pharma's Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $200.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 29.84% year-over-year to $200.5 million; the TTM value through Dec 2025 reached $841.8 million, down 21.33%, while the annual FY2025 figure was $200.5 million, 29.84% down from the prior year.
  • Liabilities and Shareholders Equity reached $200.5 million in Q4 2025 per URGN's latest filing, up from $185.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $301.9 million in Q3 2024 to a low of $95.4 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $178.7 million, with a median of $172.0 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 41.64% in 2021, then soared 195.56% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $119.7 million in 2021, then grew by 13.26% to $135.6 million in 2022, then surged by 31.48% to $178.3 million in 2023, then skyrocketed by 60.23% to $285.7 million in 2024, then decreased by 29.84% to $200.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Liabilities and Shareholders Equity are $200.5 million (Q4 2025), $185.0 million (Q3 2025), and $208.7 million (Q2 2025).